AngioDynamics Appoints George Bourne Chief Technology & Operations Officer

Mon Dec 17, 2012 5:00pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20121217:nGNXUWVMGa

ALBANY, N.Y., Dec. 17, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of
innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular
disease and oncology, today announced the appointment of George W. Bourne as Senior Vice President
and Chief Technology & Operations Officer. Previously Mr. Bourne was Senior Vice President and
Chief Technology Officer for the Company, joining in May, 2012. In his new role, Mr. Bourne will
oversee Research and Development, Sustaining Engineering, Operations and Clinical Affairs and
assumes the responsibilities of Scott Etlinger, Senior Vice President, Global Operations, who will
be leaving the company.

"George Bourne has quickly made a very positive contribution to AngioDynamics since joining our
team earlier this year," said Joseph M. DeVivo, President & CEO. "George's deep commitment to
operational excellence, combined with more than 25 years of experience in operations and R&D at
global medical device companies, provide us with a very capable and seasoned executive to lead our
R&D and operations teams as we implement our growth strategies."

Previous to joining AngioDynamics, Mr. Bourne served as VP of R&D at Hologic, and before this
served as Senior Vice President of R&D and Clinical Affairs for Navilyst Medical from its
formation in early 2008 until November 2011. His tenure was defined by focused portfolio
development and the commercialization of new products. He also served 10 years at Boston
Scientific as Vice President, R&D, of the Urology, Meditech and Oncology business units and then
as Group Vice President, R&D, for the endosurgery business group. Mr. Bourne earned his Bachelor
of Science in Biological Science and Master of Science in Plastics Engineering from the University
of Lowell, in addition to his MBA from Rivier College in Nashua, N.H. He also served in leadership
positions at Baxter Healthcare, Allegiance Healthcare and C.R. Bard.

About AngioDynamics 

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by
professional healthcare providers for vascular access, surgery, peripheral vascular disease and
oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid
management systems, vascular access products, angiographic products and accessories, angioplasty
products, drainage products, thrombolytic products and venous products. More information is
available at www.AngioDynamics.com
http://www.globenewswire.com/newsroom/ctr?d=10015961&l=5&a=www.AngioDynamics.com&u=http%3A%2F%2Fwww.angiodynamics.com%2F
.

Trademarks

AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of
AngioDynamics Inc., an affiliate or a subsidiary.

Safe Harbor 

This release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial
position, results of operations, cash flows, business strategy, budgets, projected costs, capital
expenditures, products, competitive positions, growth opportunities, plans and objectives of
management for future operations, as well as statements that include the words such as "expects,"
"reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or
variations of such words and similar expressions, are forward-looking statements. These forward
looking statements are not guarantees of future performance and are subject to risks and
uncertainties. Investors are cautioned that actual events or results may differ from
AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics
include, without limitation, the ability of AngioDynamics to develop its existing and new
products, technological advances and patents attained by competitors, future actions by the FDA or
other regulatory agencies, domestic and foreign health care reforms and government regulations,
results of pending or future clinical trials, overall economic conditions, the results of on-going
litigation, the effects of economic, credit and capital market conditions, general market
conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing
from group purchasing organizations and competition, the ability of AngioDynamics to integrate
purchased businesses, including Navilyst Medical and its products, R&D capabilities,
infrastructure and employees as well as the risk factors listed from time to time in
AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the
year ended May 31, 2012. AngioDynamics does not assume any obligation to publicly update or revise
any forward-looking statements for any reason.

CONTACT: Investor Relations Contacts:
         EVC Group, Inc.
         Jamar Ismail/Robert Jones
         (415) 568-9348; (646) 201-5447
         jismail@evcgroup.com;
         bjones@evcgroup.com
         
         Media Contact:
         EVC Group, Inc.
         Amy Phillips
         (412) 327-9499
         aphillips@evcgroup.com